Breakthroughs in Melanoma From ESMO Virtual Congress 2020

Source: Medscape, November 2020

Caroline Robert, MD, PhD, from the Gustave Roussy Cancer Campus in Paris, France, provides her take on the most important and clinically relevant studies on melanoma that were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The conference was held online because of the COVID-19 pandemic.

First, Dr Robert discusses two studies in treatment-naive patients with advanced melanoma. COMBI-i looked at spartalizumab plus dabrafenib and trametinib, while SECOMBIT examined the sequencing of targeted therapy and immunotherapy, both in patients with BRAF V600 mutations.

READ THE ORIGINAL FULL ARTICLE